See http://www.chinairr.org/report/r10/r1006/2011/04-86351.html for details.
Name of the report: 20 1 1-20 15: China Pharmaceutical Intermediates Market Operation Situation and Investment Strategy Consulting Research Report.
Keywords: pharmaceutical intermediate market analysis industry research industry research industry analysis research report
Release date: 2011-1/
catalogue
The first chapter is the analysis of the world pharmaceutical intermediate industry in 20 10 1 year.
Section 1 20 10 Overview of World Pharmaceutical Industry 1
I. New progress made in the world pharmaceutical industry 1
Second, the size of the world pharmaceutical market is 1.
Third, the world's major pharmaceutical market sales 2
Four, the world's top ten enterprises sales analysis 3 pages
The second quarter 20 10 world pharmaceutical intermediate industry market development pattern 6
I. Research Progress of World Pharmaceutical Intermediates Market 6
Second, the dynamic analysis of the world pharmaceutical intermediate market 7
Three. Dynamic analysis of the development of the world pharmaceutical intermediate market 7
Section 3 20 1 1-20 15 Analysis of the development trend of the world pharmaceutical intermediate industry 7
Chapter II Analysis of Market Development Environment of Pharmaceutical Intermediates Industry in China 20 10 9
The first quarter 20 10 China macroeconomic environment analysis 9
I. Analysis of China's GDP 9
Second, China pharmaceutical industry economic indicators analysis 10
Three. Consumer price index analysis 17
Four. Income analysis of urban and rural residents 18
Verb (abbreviation of verb) Total retail sales of social consumer goods 19
Six, the whole society investment in fixed assets analysis 2 1
Seven, import and export volume and growth rate analysis 23 pages
The second quarter 20 10 China pharmaceutical intermediate market policy environment analysis 24
I. Industrial policies and regulations 24
Second, the relevant industrial policies on page 29
Chapter III 20 103 1 Analysis of the overall operation pattern of China pharmaceutical industry.
Section 1 Overview of the Development of Pharmaceutical Industry in China 3 1
I. Development of Pharmaceutical Industry in China in the Past 30 Years of Reform and Opening-up 3 1
Two, China pharmaceutical industry is in a critical period of adjustment and upgrading 3 1.
Third, the development of multinational pharmaceutical companies in China pharmaceutical market 3 1
Four, the regulatory role of the government in the transformation of China pharmaceutical industry 34 pages.
Verb (abbreviation of verb) Analysis of the present situation of integrated traditional Chinese and western medicine on page 38
Section 2 20 10 Overview of the present situation of pharmaceutical industry in China 40
I. Pharmaceutical enterprises 40
1, multinational pharmaceutical companies accelerate their layout in China 40
2. Income of domestic pharmaceutical enterprises 4 1
3. China pharmaceutical enterprises regional cluster distribution 44 pages.
Two, China pharmaceutical market circulation 45 pages.
Third, in the pharmaceutical market in China, the medical expenses of patients increased by 45%.
Four, China pharmaceutical retail market analysis 46 pages
The third quarter 20 10 China pharmaceutical products main foreign trade market analysis 47
I. Analysis of China-India Pharmaceutical Trade Market 47
Second, the Sino-German pharmaceutical trade analysis 48 pages
Three, the Sino-British pharmaceutical trade analysis of 50 pages
Four. Sino-French pharmaceutical trade analysis 50 pages
Verb (abbreviation of verb) Analysis of Sino-Russian medical trade 5 1
The fourth chapter 20 10 China pharmaceutical intermediate industry market situation analysis 52.
The first quarter 20 10 China pharmaceutical intermediate industry development dynamic analysis 52
1. Focus of 20 10 National Seminar on Research and Development Progress and Market Prospect of Pharmaceutical Intermediates 52
Second, extend the industrial chain to build an intermediate chemical leader 54
Section 2 20 10 Overview of the current situation of pharmaceutical intermediates industry in China 55
I. Scale and ownership of pharmaceutical intermediate production enterprises in China 55
Second, the geographical distribution of production enterprises concentrated distribution 56
1, Taizhou, Zhejiang 56
2, Jiangsu Jintan 56
Three, pharmaceutical intermediates new product upgrade and production technology research 56 pages
Four. Pharmaceutical intermediate production profit 57
Five, pharmaceutical intermediates and new materials production project 59
The third quarter 20 10 China pharmaceutical intermediates market operation dialysis 60
First, the development of new varieties of pharmaceutical intermediates in China 60 pages
Two, China pharmaceutical intermediates demand analysis 60 pages.
Iii. Analysis of Import and Export Trade of Pharmaceutical Intermediates in China 6 1
1, market analysis of imported varieties 6 1
2, export varieties market analysis 74
The fourth quarter 20 10 China pharmaceutical intermediates industry hot issues 88
First, the pressure on production enterprises to build environmental protection treatment facilities has increased by 88
Second, the research and development of new pharmaceutical intermediates 88
Three. Coping strategy analysis 89
The fifth chapter 20 10 China pharmaceutical intermediate industry new technology and technology research 90.
The first quarter 20 10 China pharmaceutical intermediates industry hot technology research 90
A, directional nitrification technology 90
Second, the condensation technology 90
III. Control of Oxidation Technology 90
Four. Fluorination technology 90
V. Hydroreduction Technology 9 1
In the second quarter, the research progress of new processes, routes and technologies for the synthesis of key pharmaceutical intermediates 9 1
First, the synthesis of raw materials and intermediates of cephalosporins has achieved initial results.
Second, fluorine-containing drugs are an important trend of development 9 1
Thirdly, great progress has been made in the study of chiral compounds.
Chapter VI Monitoring and Analysis of the Main Data of China Chemical Pharmaceutical Manufacturing Industry in 2006-2012006 (27 10) 93
The first section 2006-201kloc-0/June China chemical manufacturing scale analysis 93
First, the number of enterprises growth analysis 93
Second, the number of employees growth analysis 93
Third, the analysis of asset scale growth 93
The second quarter 2011June China chemical manufacturing structure analysis 94
I. Analysis of Enterprise Quantity Structure 94
1, different types of analysis 94
2, different ownership analysis 94
Second, the sales revenue structure analysis 95
1, different types of analysis 95
2, different ownership analysis 95
The third quarter 2006-201KLOC-0/June China chemical raw material medicine manufacturing output value analysis 96
A, finished product growth analysis 96
Second, the industrial sales output value analysis 96
Three, export delivery value analysis on page 96
The fourth quarter 2006-201kloc-0/June China chemical manufacturing cost analysis 97
I. Cost of Sales Analysis 97
Two. Cost analysis 97
The fifth quarter 2006-201kloc-0/June China chemical manufacturing profitability analysis 97
I. Analysis of main profit indicators 97
Second, the main profitability index analysis 98
The seventh chapter 20 10 China pharmaceutical intermediate industry hot product market dialysis 99
The first section phenylacetic acid 99
In the second quarter, fluorine-containing pyridine intermediates 100
Amino acids in the third quarter 10 1
Chapter VIII Market Research of Synthetic and Semi-synthetic APIs and Intermediates in China in 20 102.
Section 1 Antibiotics and Intermediates 102
I. β -lactam drugs and intermediates 102
Second, sulfonamides, synergists and intermediates 103
Iii. Fluoroquinolones Antibiotics and Their Intermediates 104
IV. Nitrofuran Antibiotics and Their Intermediates 105
V. Anti-TB Drugs and Intermediates 106
VI. Antifungal Drugs and Intermediates 106
Seven. Antiviral drugs and intermediates 106
Section 2 Antipyretic and Analgesic Drugs and Their Intermediates 107
Section 3 Vitamins and Intermediates 108
Section IV Antiparasitic Drugs and Intermediates 1 10
Section 5 Family Planning Drugs, Hormones and Intermediates 1 1 1
Section 6 Cardiovascular Drugs and Intermediates 1 12
Section 7 Central nervous system drugs and intermediates 1 13
Section 8 Drugs and Intermediates of Digestive System 1 14
Chapter IX Analysis of Competition Pattern of Pharmaceutical Intermediates Market in China 20 10 15
The first section 2065,438+00 China pharmaceutical intermediate industry competition status 65,438+05.
First, disorderly competition is becoming increasingly fierce 1 15
Two. Analysis of International Competitiveness of Pharmaceutical Intermediates Industry in China 1 15
Third, the competitiveness of pharmaceutical intermediate industry needs to be improved 1 16
In the second quarter, 20 10, concentration analysis of pharmaceutical intermediate industry in China 1 17.
In the third quarter, 20 1 1-20 15 Analysis of the competition trend of pharmaceutical intermediate industry in China 1 18.
Chapter 10: Competitiveness and Key Data Analysis of China Pharmaceutical Intermediates Advantage Production Enterprises 20 10 20 120
Section 1 Zibo Jincheng Industrial Co., Ltd. 120
I. Enterprise Profile 120
II. Analysis of Main Economic Indicators of Enterprises 120
Three. Analysis of enterprise profitability 12 1
Four. Analysis of corporate solvency 12 1
Verb (abbreviation of verb) Analysis of enterprise operation ability 122
An analysis of enterprise growth ability with intransitive verbs 122
Chongqing Ziguang Chemical Co., Ltd. 123 Section 2
I. Enterprise Profile 123
II. Analysis of Main Economic Indicators of Enterprises 123
Three. Analysis of enterprise profitability 124
Iv. Analysis of corporate solvency 124
Verb (abbreviation of verb) Analysis of enterprise operation ability 125
An analysis of enterprise growth ability with intransitive verbs 125
Section 3 Shandong Lu Kang Pharmaceutical Group Co., Ltd. 125
I. Enterprise Profile 125
II. Analysis of Main Economic Indicators of Enterprises 127
Three. Analysis of enterprise profitability 127
Four. Analysis of corporate solvency 128
Verb (abbreviation of verb) Analysis of enterprise operation ability 128
An analysis of enterprise growth ability with intransitive verbs 128
Section 4 Donggang Industry and Trade Group Co., Ltd. 129
I. Enterprise Profile 129
II. Analysis of Main Economic Indicators of Enterprises 129
III. Profitability Analysis of Enterprises 130
Iv. Analysis of corporate solvency 130
Verb (abbreviation of verb) Analysis of enterprise operation ability 13 1
Analysis of enterprise growth ability of intransitive verbs 13 1
Section 5 Jiangxi Tianxin Pharmaceutical Chemical Co., Ltd. 13 1
I. Enterprise Profile 13 1
II. Analysis of Main Economic Indicators of Enterprises 132
III. Profitability Analysis of Enterprises 132
Iv. Analysis of the solvency of enterprises 133
Verb (abbreviation of verb) Analysis of enterprise operation ability 133
An analysis of the growth ability of enterprises with intransitive verbs 133
Section 6 Shijiazhuang Lihai Flavor Co., Ltd. 134
I. Enterprise Profile 134
II. Analysis of Main Economic Indicators of Enterprises 134
III. Profitability Analysis of Enterprises 135
Iv. Analysis of corporate solvency 135
Verb (abbreviation of verb) Analysis of enterprise operation ability 136
An analysis of the growth ability of enterprises with intransitive verbs 136
Section 7 Zhejiang Yongtai Technology Co., Ltd. 137
I. Enterprise Profile 137
II. Analysis of Main Economic Indicators of Enterprises 137
Three. Profitability Analysis of Enterprises 138
Four. Analysis of corporate solvency 139
V. Analysis of Enterprise Operation Capability 140
VI. Analysis of Enterprise Growth Ability 140
Section 8 Zhejiang Tianyu Pharmaceutical Co., Ltd. 14 1
I. Enterprise Profile 14 1
Second, the main economic indicators of enterprises 14 1
Iii. Profitability Analysis of Enterprises 142
Iv. Analysis of solvency of enterprises 142
Verb (abbreviation of verb) Analysis of enterprise operation ability 143
An analysis of enterprise growth ability with intransitive verbs 143
Section 9 Wujiang Meiyan Sanyou Dye Chemical Co., Ltd. 143
I. Enterprise Profile 143
II. Analysis of Main Economic Indicators of Enterprises 144
Three. Analysis of enterprise profitability 144
Iv. Analysis of solvency of enterprises 145
Verb (abbreviation of verb) Analysis of enterprise operation ability 145
An analysis of enterprise growth ability with intransitive verbs 145
Section 10 Hebei Baiqi Pharmaceutical Co., Ltd. 146
I. Enterprise Profile 146
II. Analysis of Main Economic Indicators of Enterprises 146
Three. Analysis of enterprise profitability 147
Iv. Analysis of solvency of enterprises 147
Verb (abbreviation of verb) Analysis of enterprise operation ability 148
An analysis of enterprise growth ability with intransitive verbs 148
Chapter XI 2011-2015 Development Trend and Prospect of Pharmaceutical Intermediates Industry in China 149
Section 1 20 1 1-20 15 Analysis on the Development Prospect of Pharmaceutical Intermediates Industry in China 149.
I. Forecast of the pharmaceutical industry in China 149.
Second, the pharmaceutical intermediates new product research and development prospects forecast 150
Section 2 20 1 1-20 15 development direction of pharmaceutical intermediate industry in China 15 1.
1. The technical content plays a decisive role in the production of pharmaceutical intermediates 15 1.
Two. Develop and produce intermediates and APIs for products whose patents are about to expire 15 1.
Iii. Development and production of pharmaceutical intermediates during the patent period 15 1
IV. Improving the production level of API intermediates 152
Section 3 20 1 1-20 15 China pharmaceutical intermediate industry market forecast and analysis 152.
I. Market Supply and Demand Forecast of Pharmaceutical Intermediates Industry 152
II. Forecast and Analysis of Import and Export Trade of Pharmaceutical Intermediates 153
The fourth quarter 20 1 1-20 15 China pharmaceutical intermediate market profit forecast analysis 153.
Section 5 2011-2065438+2065438 Suggestions for the development of pharmaceutical intermediate enterprises in China in 2005 154.
First of all, we should change our ideas 154.
Second, strengthen contact with domestic and foreign pharmaceutical enterprises 154
Thirdly, it will gradually develop into the production of API 154.
IV. Strengthening Technical Reserve 154
Verb (abbreviation of verb) Development direction of pharmaceutical intermediates 155
Chapter 12 20 1 1-20 15 Research on Investment Strategy of Pharmaceutical Intermediates Industry in China 156
Section 1 20 10 China pharmaceutical intermediate industry investment survey 156
I. Characteristics of Investment in Pharmaceutical Industry in China 156
II. Analysis on the Investment Environment of Pharmaceutical Intermediates Industry in China 157
Section 2 20 1 1-20 15 analysis of investment opportunities in China pharmaceutical intermediate industry 158.
I. Analysis of Hot Investment Spots of Pharmaceutical Intermediates 158
Two. Analysis of regional investment potential of pharmaceutical intermediates 158
Section 3 20 1 1-20 15 investment risk and prevention of pharmaceutical intermediate industry in China 158.
I. Macro-control Policy Risks 158
Second, the market competition risk 159
Iii. Risk of raw material supply 159
Four. Risk of market operation mechanism 16 1
Section IV Expert Investment Suggestions 16 1
..........
For more information, please visit China Industrial Research Report Network! I hope I can help you!